Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies

Mutating anti–HIV-1 broadly neutralizing antibodies increases their breadth and reduces pathways for viral escape through mutation.

[1]  Wolfgang Kabsch,et al.  Integration, scaling, space-group assignment and post-refinement , 2010, Acta crystallographica. Section D, Biological crystallography.

[2]  Michael S. Seaman,et al.  Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies , 2012, Proceedings of the National Academy of Sciences.

[3]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[4]  M. Carrington,et al.  Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection , 2007, Journal of Virology.

[5]  F. Pereyra,et al.  A method for identification of HIV gp140 binding memory B cells in human blood. , 2009, Journal of immunological methods.

[6]  A. Haase,et al.  Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice , 2008, PLoS medicine.

[7]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[8]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[9]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[10]  A. Miele,et al.  Free energy of burying hydrophobic residues in the interface between protein subunits. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  H. Kräusslich,et al.  T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. , 2005, Virology.

[12]  M. Manz.  Human-hemato-lymphoid-system mice: opportunities and challenges. , 2007, Immunity.

[13]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[14]  J. Mullins,et al.  Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies , 2013, AIDS.

[15]  L. Stamatatos,et al.  Broadly Neutralizing Antibodies Developed by an HIV-Positive Elite Neutralizer Exact a Replication Fitness Cost on the Contemporaneous Virus , 2012, Journal of Virology.

[16]  Markus G. Manz,et al.  Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2−/−γc−/− mice , 2006, Proceedings of the National Academy of Sciences.

[17]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[18]  John P. Moore,et al.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 , 2003, Nature Medicine.

[19]  P. Hofman,et al.  The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. , 2006, Current medicinal chemistry.

[20]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[21]  Ron Diskin,et al.  Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity , 2010, Nature Structural &Molecular Biology.

[22]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[23]  D. Burton,et al.  Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.

[24]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[25]  Philip R. Johnson,et al.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys , 2009, Nature Medicine.

[26]  D. Montefiori,et al.  Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.

[27]  Christine Hogan,et al.  Determining the relative efficacy of highly active antiretroviral therapy. , 2003, The Journal of infectious diseases.

[28]  A. Trkola,et al.  In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective Titers , 2007, Journal of Virology.

[29]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[30]  Ron Diskin,et al.  Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.

[31]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[32]  David Baltimore,et al.  Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.

[33]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[34]  Ron Diskin,et al.  HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.

[35]  Ron Diskin,et al.  Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 , 2012, Proceedings of the National Academy of Sciences.

[36]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[37]  D. Goodsell.  Broadly Neutralizing Antibodies , 2014 .

[38]  Michael S. Seaman,et al.  HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes , 2012, Journal of Virology.

[39]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.